Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ValenzaBio, Inc.
Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.
Weak financing sentiment for Korean bioventures continues this year with sharply lower fund inflows from venture capital and other investors, as well as delayed or withdrawn IPOs, in Q2. Amyloid Solution, Rznomics, and UPPthera were among the top fundraisers.
German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.
- Large Molecule